Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT05312255

Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma

Led by Roswell Park Cancer Institute · Updated on 2025-12-01

175

Participants Needed

1

Research Sites

260 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This clinical trial investigates the effect of non-chemotherapeutic interventions in patients with multiple myeloma or MDS. Non-chemotherapeutic interventions such as physical activity and nutritional interventions (e.g., modifications in diet) have been shown to positively affect the immune system and improve overall quality of life. Another purpose of this study is for researchers to learn how the addition of a beta-blocker (propranolol) to the standard treatment regimen in patients with newly diagnosed multiple myeloma affects immune response and quality of life. A study from the Mayo Clinic looked at multiple myeloma patients who were on a beta-blocker while undergoing chemotherapy and found that the use of a beta-blocker resulted in improved patient survival outcomes. Non-chemotherapeutic treatment options may help decrease symptoms and improve quality of life for patients with multiple myeloma.

CONDITIONS

Official Title

Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older
  • Eastern Cooperative Oncology Group (ECOG) Performance Status: Module A and D: 0-1; Modules B and C: 0-2
  • For Modules A, B, and C: diagnosis of smoldering multiple myeloma, multiple myeloma, or plasma cell leukemia
  • For Module D: diagnosis of low-risk myelodysplastic syndrome (MDS) not requiring transfusions
  • No signs of comorbidities, myeloma symptoms, or treatment side effects that pose danger as judged by a physician
  • Ability to understand and follow study procedures
  • Willingness to provide informed consent
  • For Modules A and D: access to a computer or tablet with camera, microphone, speakers, and internet
  • For Module C: newly diagnosed multiple myeloma patients needing treatment and not yet started systemic therapy
  • For Module C: female participants of child-bearing potential must have a negative pregnancy test and agree to use contraception; male participants with partners of child-bearing potential must agree to use contraception
  • For Module D: MDS patients not needing transfusions within 8 weeks prior to enrollment
Not Eligible

You will not qualify if you...

  • Major comorbidities posing danger or risk of progression during the study, including cardiac, pulmonary, infectious diseases, psychiatric illness, or social situations limiting compliance
  • Unwillingness or inability to follow study protocol
  • Any condition that makes participation unsafe or unsuitable as judged by the investigator
  • For Module A: current symptomatic pathological fractures or severe musculoskeletal instability
  • For Module A: acute bone instability as assessed by imaging and surgeon evaluation
  • For Module B: clinical signs of malnutrition (BMI less than 18)
  • For Module B: special or physician-prescribed diets
  • For Module B: diabetes treated with glucose-lowering medications or insulin
  • For Module B: any condition that contraindicates food restriction
  • For Module C: current or recent (within 3 months) use of beta-blockers
  • For Module C: contraindications to beta-blocker use, including specific heart conditions, uncontrolled depression, unstable heart failure, hypotension, severe asthma or COPD, uncontrolled diabetes, symptomatic peripheral arterial disease, untreated pheochromocytoma, current use of certain heart medications, or presence of pacemaker
  • For Module C: pregnancy or nursing
  • For Module D: cardiovascular disease limiting exercise readiness as judged by a cardiologist

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Roswell Park Cancer Institute

Buffalo, New York, United States, 14263

Actively Recruiting

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

5

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here